Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children
复制标题
DOI：
10.1053/j.gastro.2006.12.003
复制
发表时间：
2007-03-01
期刊：
影响因子：
29.4
通讯作者：
Baldassano, Robert
中科院分区：
文献类型：
--
作者：
Hyams, Jeffrey;Crandall, Wallace;Baldassano, Robert
背景和目的：REACH 研究评估了英夫利昔单抗对中度至重度活动性克罗恩病儿童的安全性和有效性。方法：儿科克罗恩病活动指数 (PCDAI) 评分 > 30 的患者 (n = 112) 在第 0、2 和 6 周接受英夫利昔单抗 5 mg/kg。第 10 周治疗有反应的患者被随机分配至第 46 周，每 8 或 12 周接受英夫利昔单抗 5 mg/kg。需要同时使用免疫调节剂。临床缓解（PCDAI 评分较基线下降 15 分；总分：530）和临床缓解（PCDAI 评分
Background & Aims: The REACH study evaluated the safety and efficacy of infliximab in children with moderately to severely active Crohn's disease. Methods: Patients (n = 112) with a Pediatric Crohn's Disease Activity Index (PCDAI) score > 30 received infliximab 5 mg/kg at weeks 0, 2, and 6. Patients responding to treatment at week 10 were randomized to infliximab 5 mg/kg every 8 or 12 weeks through week 46. A concurrent immunomodulator was required. Clinical response (decrease from baseline in the PCDAI score 15 points; total score :530) and clinical remission (PCDAI score